Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by analysts at Wells Fargo & Co from a “market perform” rating to an “underperform” rating in a research note issued on Friday. They currently have a $17.00 price target on the stock. Wells Fargo & Co’s target price suggests a potential downside of 13.18% from the stock’s current price.
Other equities research analysts have also recently issued reports about the stock. BTIG Research increased their target price on shares of Teva Pharmaceutical Industries to $20.00 in a research report on Friday, December 15th. Gabelli reiterated a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, September 13th. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Evercore ISI set a $38.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Wednesday, October 25th. Finally, Goldman Sachs Group upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Friday, December 15th. Seven equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $21.16.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $19.58 on Friday. The company has a market cap of $19,390.00, a PE ratio of -3.34 and a beta of 0.54. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries has a 12-month low of $10.85 and a 12-month high of $38.15.
TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries (TEVA) Rating Lowered to Underperform at Wells Fargo & Co” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3126684/wells-fargo-co-downgrades-teva-pharmaceutical-industries-teva-to-sell.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.